Reuters has published “Navigating the Parallel Path of Patent Litigation Alongside the Inflation Reduction Act,” an article by Akin partners Michael P. Kahn and Craig B. Bleifer and counsel Caitlin E. Olwell. The lawyers hail from the firm’s market-leading intellectual property (IP) and health care & life sciences groups.
In the article, the authors discuss the impact of the Inflation Reduction Act (IRA) on patent litigation involving pharmaceuticals and biologics. The IRA complicated an already “complex interplay between patent law, court procedures and Food and Drug Administration (FDA)/regulatory regimes.”
The authors expect that the new IRA regulatory regime will be relevant to patent litigations concerning “selected” drug products and that practitioners should pay close attention in the coming months and consider employing a coordinated approach involving regulatory, patent litigation and business teams.
To read the complete article, click here.